secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001140361-23-022489
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics acquires Exacis Biotherapeutics' IP assets in stock-and-contingent deal
--------------------------------------------------------------------------------

- Eterna issued 69,343 shares to Exacis at closing; shares subject to 12-month lockup.
- Contingent milestone: if market cap hits $100M, additional $2M in shares; at $200M, another $2M in shares.
- Eterna to pay Exacis 20% of sublicensing revenue received within 5 years, capped at $45M.
- CEO Matthew Angel is co-founder of Factor Bioscience (Exacis parent); director Gregory Fiore is CEO of Exacis; deal approved by audit committee and disinterested directors.
- Eterna assumes only post-closing liabilities under the purchased license; Exacis retains other liabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123022489/0001140361-23-022489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123022489/brhc20052311_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-022489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer